Aldeyra The (ALDX) - Net Assets
Based on the latest financial reports, Aldeyra The (ALDX) has net assets worth $37.89 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($47.54 Million) and total liabilities ($9.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Aldeyra The PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $37.89 Million |
| % of Total Assets | 79.69% |
| Annual Growth Rate | N/A |
| 5-Year Change | -78.49% |
| 10-Year Change | 104.39% |
| Growth Volatility | 127.78 |
Aldeyra The - Net Assets Trend (2011–2025)
This chart illustrates how Aldeyra The's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Aldeyra The market cap and net worth.
Annual Net Assets for Aldeyra The (2011–2025)
The table below shows the annual net assets of Aldeyra The from 2011 to 2025. Also explore Aldeyra The annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $44.25 Million | -37.68% |
| 2024-12-31 | $71.00 Million | -40.73% |
| 2023-12-31 | $119.80 Million | -20.67% |
| 2022-12-31 | $151.01 Million | -26.60% |
| 2021-12-31 | $205.74 Million | +245.72% |
| 2020-12-31 | $59.51 Million | +23.76% |
| 2019-12-31 | $48.08 Million | -44.49% |
| 2018-12-31 | $86.62 Million | +118.73% |
| 2017-12-31 | $39.60 Million | +82.92% |
| 2016-12-31 | $21.65 Million | -12.98% |
| 2015-12-31 | $24.88 Million | +295.90% |
| 2014-12-31 | $6.28 Million | +289.14% |
| 2013-12-31 | $1.61 Million | +106.42% |
| 2012-12-31 | $-25.15 Million | -977.50% |
| 2011-12-31 | $-2.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aldeyra The's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46844048300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $60.16K | 0.14% |
| Other Components | $528.15 Million | 1193.54% |
| Total Equity | $44.25 Million | 100.00% |
Aldeyra The Competitors by Market Cap
The table below lists competitors of Aldeyra The ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tonymoly Co Ltd
KO:214420
|
$83.26 Million |
|
U&I Corporation
KQ:056090
|
$83.27 Million |
|
Agabang&Company
KQ:013990
|
$83.30 Million |
|
Chegg Inc
NYSE:CHGG
|
$83.38 Million |
|
Mitchell Services Ltd
AU:MSV
|
$83.24 Million |
|
Nexstim Oyj
HE:NXTMH
|
$83.24 Million |
|
American Lithium Corp
V:LI
|
$83.22 Million |
|
Sterling Tools Limited
NSE:STERTOOLS
|
$83.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aldeyra The's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 71,004,871 to 44,250,390, a change of -26,754,481 (-37.7%).
- Net loss of 33,846,661 reduced equity.
- Other comprehensive income decreased equity by 37,442.
- Other factors increased equity by 7,129,622.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-33.85 Million | -76.49% |
| Other Comprehensive Income | $-37.44K | -0.08% |
| Other Changes | $7.13 Million | +16.11% |
| Total Change | $- | -37.68% |
Book Value vs Market Value Analysis
This analysis compares Aldeyra The's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.87x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-0.49 | $1.38 | x |
| 2012-12-31 | $-20.95 | $1.38 | x |
| 2013-12-31 | $-0.40 | $1.38 | x |
| 2014-12-31 | $1.63 | $1.38 | x |
| 2015-12-31 | $2.88 | $1.38 | x |
| 2016-12-31 | $1.91 | $1.38 | x |
| 2017-12-31 | $2.49 | $1.38 | x |
| 2018-12-31 | $3.99 | $1.38 | x |
| 2019-12-31 | $1.77 | $1.38 | x |
| 2020-12-31 | $1.75 | $1.38 | x |
| 2021-12-31 | $3.81 | $1.38 | x |
| 2022-12-31 | $2.59 | $1.38 | x |
| 2023-12-31 | $2.03 | $1.38 | x |
| 2024-12-31 | $1.19 | $1.38 | x |
| 2025-12-31 | $0.74 | $1.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aldeyra The utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -76.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.63x
- Recent ROE (-76.49%) is below the historical average (-50.94%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.14 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-20.56 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $13.25 Million |
| 2014 | -82.54% | 0.00% | 0.00x | 1.40x | $-5.82 Million |
| 2015 | -48.60% | 0.00% | 0.00x | 1.13x | $-14.58 Million |
| 2016 | -86.37% | 0.00% | 0.00x | 1.16x | $-20.86 Million |
| 2017 | -56.42% | 0.00% | 0.00x | 1.12x | $-26.30 Million |
| 2018 | -44.90% | 0.00% | 0.00x | 1.10x | $-47.55 Million |
| 2019 | -126.51% | 0.00% | 0.00x | 1.57x | $-65.64 Million |
| 2020 | -63.11% | 0.00% | 0.00x | 1.40x | $-43.50 Million |
| 2021 | -28.08% | 0.00% | 0.00x | 1.13x | $-78.35 Million |
| 2022 | -41.07% | 0.00% | 0.00x | 1.20x | $-77.13 Million |
| 2023 | -31.34% | 0.00% | 0.00x | 1.24x | $-49.52 Million |
| 2024 | -78.66% | 0.00% | 0.00x | 1.47x | $-62.95 Million |
| 2025 | -76.49% | 0.00% | 0.00x | 1.63x | $-38.27 Million |
Industry Comparison
This section compares Aldeyra The's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aldeyra The (ALDX) | $37.89 Million | 0.00% | 0.25x | $83.25 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary… Read more